Positions

Overview

  • Dr. Ovalle is a Professor of Medicine and Director of the Division of Endocrinology, Diabetes & Metabolism at the University of Alabama at Birmingham (UAB) School of Medicine. In addition to maintaining a large and busy clinical practice, he serves as the Director of the Multidisciplinary Comprehensive Diabetes Clinic, and Director of Diabetes and Glycemic Control Programs at UAB Hospital.

    He is a Fellow of the American College of Endocrinology (FACE), and an active member of the American Association of Clinical Endocrinologists (AACE) where he has served in multiple national committees and is Past-President of the Southern States Chapter of the American Association of Clinical Endocrinologists (AACE).

    Dr. Ovalle has published extensively in the areas of diabetes and metabolism, serves as a member of the editorial board of multiple scientific publications, and is currently the U.S. Editor-in-Chief for the journal Diabetes Therapy.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 American Diabetes Association 2019 Conference Podcast With the Editor-in-Chief: What Are the Outcomes from ADA This Year and What Are the Future Developments in Diabetes?Diabetes Therapy.  10:1177-1179. 2019
    2019 Acute Effects of Exercise Intensity on Insulin Sensitivity under Energy BalanceMedicine and science in sports.  51:988-994. 2019
    2019 A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019Diabetes Therapy.  10. 2019
    2019 Dapagliflozin and cardiovascular outcomes in type 2 diabetesNew England Journal of Medicine.  380:347-357. 2019
    2018 First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetesDiabetes Care.  41:2396-2403. 2018
    2018 Verapamil and beta cell function in adults with recent-onset type 1 diabetesNature Medicine.  24:1108-1112. 2018
    2018 Understanding concentrated insulins: a systematic review of randomized controlled trialsCurrent Medical Research and Opinion.  34:1029-1043. 2018
    2018 Daily opioid analgesic use reduces blood insulin levelsJournal of Opioid Management.  14:165-170. 2018
    2018 The Role of Perceived Discrimination and Other Psychosocial Factors in Explaining Diabetes Distress Among Older African American and White Adults.Journal of Applied Gerontology.  733464817750273. 2018
    2017 Effects of acute hyperinsulinemia on skeletal muscle mitochondrial function, reactive oxygen species production, and metabolism in premenopausal womenMetabolism.  77:1-12. 2017
    2017 Association of multiple chronic conditions and pain among older black and white adults with diabetes mellitusBMC Geriatrics.  17. 2017
    2017 Cardiovascular efficacy and safety of bococizumab in high-risk patientsNew England Journal of Medicine.  376:1527-1539. 2017
    2017 SYNTAX Score and Long-Term Outcomes: The BARI-2D TrialJournal of the American College of Cardiology.  69:395-403. 2017
    2016 Erratum: Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: A randomized, controlled trial (Nutrition and Metabolism (2016) 13:2 DOI 10.1186/s12986-016-0062-5)Nutrition & Metabolism.  13. 2016
    2016 Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: A randomized, controlled trialNutrition & Metabolism.  13. 2016
    2016 Correlates of Depressive Symptoms in Older Adults with DiabetesJournal of Diabetes Research.  2016. 2016
    2015 Associations of social support and self-efficacy with quality of life in older adults with diabetesJournal of Gerontological Nursing.  41:21-29. 2015
    2015 Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D trialInternational Journal of Endocrinology.  2015. 2015
    2015 Stroke Symptoms with Absence of Recognized Stroke Are Associated with Cognitive Impairment and Depressive Symptoms in Older Adults with DiabetesJournal of Geriatric Psychiatry and Neurology.  29:142-148. 2015
    2014 Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulinJournal of Diabetes Science and Technology.  8:821-829. 2014
    2014 Determinants of successful glycemic control among participants in the BARI 2D Trial: A Post-hoc AnalysisJournal of Diabetes and its Complications.  28:101-109. 2014
    2014 Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOSMetabolism2014
    2014 Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOSMetabolism.  63:1257-1264. 2014
    2014 Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 studyLancet Diabetes and Endocrinology.  2:289-297. 2014
    2013 Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: Findings from a population-based cohort studyInternational Journal of Cardiology.  168:3616-3622. 2013
    2013 Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOSClinical Endocrinology.  79:550-557. 2013
    2013 Metanx in type 2 diabetes with peripheral neuropathy: A randomized trialAmerican Journal of Medicine.  126:141-149. 2013
    2013 Net Food Imports and Obesity in Selected Latin American & Caribbean Countries 2013
    2012 Ethnic differences in glucose disposal, hepatic insulin sensitivity, and endogenous glucose production among African American and European American womenMetabolism.  61:634-640. 2012
    2012 Race differences in the association of oxidative stress with insulin sensitivity in African- and European-American womenObesity Research.  20:972-977. 2012
    2012 Cardiometabolic Risk, Knowledge, Risk Perception, and Self-Efficacy among American Indian Women with Previous Gestational DiabetesJOGN nursing; journal of obstetric, gynecologic, and neonatal nursing.  41:246-257. 2012
    2011 A propensity-matched study of the association of diabetes mellitus with incident heart failure and mortality among community-dwelling older adultsAmerican Journal of Cardiology.  108:1747-1753. 2011
    2011 A web-based diabetes intervention for physician: A cluster-randomized effectiveness trialInternational Journal for Quality in Health Care.  23:682-689. 2011
    2011 Cardiovascular implications of antihyperglycemic therapies for type 2 diabetesClinical Therapeutics.  33:393-407. 2011
    2011 Age-related changes in insulin sensitivity and β-cell function among European-American and African-American womenObesity Research.  19:528-535. 2011
    2011 Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: A propensity-matched studyEuropean Journal of Heart Failure.  13:200-206. 2011
    2011 Patient complexity and diabetes quality of care in rural settingsJournal of the National Medical Association.  103:234-240. 2011
    2010 Clinical approach to the patient with diabetes mellitus and very high insulin requirementsDiabetes Research and Clinical Practice.  90:231-242. 2010
    2010 Adiposity and Β-cell function: Relationships differ with ethnicity and ageObesity Research.  18:2086-2092. 2010
    2009 Cardiometabolic risk among african american women: A pilot studyJournal of Cardiovascular Nursing.  24:140-150. 2009
    2009 Latent autoimmune diabetes of adulthood (LADA): An often misdiagnosed type of diabetes mellitusJournal of the American Academy of Nurse Practioners.  21:156-159. 2009
    2008 Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucoseDiabetes Care.  31:1007-1014. 2008
    2008 Catamenial diabetic ketoacidosis and catamenial hyperglycemia: Case report and review of the literatureAmerican Journal of the Medical Sciences.  335:298-303. 2008
    2008 Uncovering imperative interventions in prediabetes and type 2 diabetesNurse Practitioner.  33:20-26. 2008
    2007 A propensity-matched study of the effect of diabetes on the natural history of heart failure: Variations by sex and ageBritish heart journal.  93:1584-1590. 2007
    2007 Reasons for not intensifying medications: Differentiating "clinical inertia" from appropriate careJournal of General Internal Medicine.  22:1648-1655. 2007
    2007 Vascular disease in paediatric type 2 diabetes: The state of the artDiabetes and Vascular Disease Research.  4:297-304. 2007
    2007 Avoiding the looming Latino/Hispanic cardiovascular health crisis: A call to actionEthnicity and Disease.  17:568-573. 2007
    2007 Elements of the metabolic syndrome: Association with insulin sensitivity and effects of ethnicityMetabolic Syndrome and Related Disorders.  5:77-86. 2007
    2007 Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action.Journal of the CardioMetabolic Syndrome.  2:238-243. 2007
    2007 Cardiovascular disease prevention and care in latino and hispanic subjectsEndocrine Practice.  13:77-85. 2007
    2007 Optimizing insulin regimesNurse Practitioner.  32:18-26. 2007
    2006 Effect of ramipril on the incidence of diabetesNew England Journal of Medicine.  355:1551-1562. 2006
    2006 Role of diet in the treatment of polycystic ovary syndromeFertility and Sterility.  85:679-688. 2006
    2006 African-American women, metabolic syndrome, and national cholesterol education program criteria: a pilot study.Journal- National Black Nurses Association.  17:9-16. 2006
    2006 Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) studyDiabetes, Obesity and Metabolism.  8:49-57. 2006
    2006 Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetesDiabetes, Obesity and Metabolism.  8:110-115. 2006
    2005 African American women, metabolic syndrome, and National Cholesterol Education Program criteria: A pilot studyNursing Research.  54:339-346. 2005
    2004 Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetesDiabetes Care.  27:2585-2589. 2004
    2004 Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetesDiabetes, Obesity and Metabolism.  6:363-366. 2004
    2004 The role of C-peptide levels in screening for latent autoimmune diabetes in adults.American Journal of Therapeutics.  11:308-311. 2004
    2002 Lipoprotein effects of different thiazolidinediones in clinical practiceEndocrine Practice.  8:406-410. 2002
    2002 Exploring the relationship between PCOS and Type 2 diabetes mellitusReferences en Gynecologie Obstetrique.  9:29-33. 2002
    2002 Thiazolidinediones: A review of their benefits and risksSouthern Medical Journal.  95:1188-1194. 2002
    2002 Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism.  4:56-59. 2002
    2002 Effect of thiazolidinediones on high-density lipoprotein subfractionsEndocrine Practice.  8:102-104. 2002
    2002 Artifactually low hemoglobin A1c caused by use of dapsoneEndocrine Practice.  8:370-372. 2002
    2002 High-dose mineralocorticoid requirements in an adrenally insufficient pregnant patient: A case reportEndocrinologist.  12:391-394. 2002
    2002 Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitusFertility and Sterility.  77:1095-1105. 2002
    2002 Long-term efficacy of triple oral therapy for type 2 diabetes mellitusEndocrine Practice.  8:271-275. 2002
    2001 Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: Review of the evidence in animals and humansEndocrine Practice.  7:135-138. 2001
    2001 Conversion from troglitazone to rosiglitazoneEndocrine Practice.  7:326. 2001
    2001 Use of soy protein supplement and resultant need for increased dose of levothyroxineEndocrine Practice.  7:193-194. 2001
    2001 Cerebellar ataxia associated with high levels of anti-glutamic acid decarboxylase antibodiesEndocrinologist.  11:233-235. 2001
    2000 How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?Endocrine Practice.  6:293-295. 2000
    2000 Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy.Endocrine Practice.  6:357-360. 2000
    2000 Late-onset troglitazone-induced hepatic dysfunction [5]Diabetes Care.  23:128-129. 2000
    2000 Postprandial rather than preprandial glucose levels should be used for adjustment of rapid-acting insulins.Endocrine Practice.  6:477-478. 2000
    1999 Hormone replacement therapy and serum uric acid (multiple letters) [3]Lancet.  354:1643-1644. 1999
    1999 Stroke management in the diabetic patientJournal of Critical Illness.  14:309-318. 1999
    1999 Gastroparesis cured by gastrectomy [4]Diabetes Care.  22:1000-1001. 1999
    1999 C-Peptide utilization in clinical practice: effect on treatment and outcome of diabetes in a series of cases.Endocrine Practice.  5:114-118. 1999
    1999 Troglitazone's effect on lipoprotein(a) levels [6]Diabetes Care.  22:859-860. 1999
    1999 Using combination therapy for type 2 diabetesIm -Morganville then Montvale Nj-.  20:20-28. 1999
    1998 Triple oral antidiabetic therapy in type 2 diabetes mellitus.Endocrine Practice.  4:146-147. 1998
    1998 Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in 1 diabetes mellitusDiabetes.  47:1472-1479. 1998
    1998 Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysisPeritoneal Dialysis International.  18:34-40. 1998
    1998 Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetesDiabetes.  47:1920-1927. 1998
    1998 Metformin lowers lipoprotein(a) levels [1]Diabetes Care.  21:2028. 1998
    1998 Troglitazone interferes with gemfibrozil's lipid-lowering action [2]Diabetes Care.  21:2028-2029. 1998

    Research Overview

  • The focus of Dr. Ovalle's research over the last 20+ years has been the areas of diabetes and energy metabolism and involves extensive experience in clinical trials concerning the pharmacologic management of diabetes mellitus and its complications, the effects of diet on insulin sensitivity and energy metabolism, and the study of novel therapies for type 1 diabetes. He is also interested in the epidemiology, classification, and pathophysiology of the less well understood sub-types of diabetes mellitus, including Latent Autoimmune Diabetes of the Adult, Monogenic Diabetes, Lipodystrophy Syndromes, and Atypical Diabetes.
  • Principal Investigator On

  • Private Grant  awarded by Sanofi US Services Inc 2018 - 2025
  • Private Grant  awarded by INTREXON T1D PARTNERS. LLC 2019 - 2024
  • Private Grant  awarded by KOWA 2017 - 2022
  • Private Grant  awarded by ASTRAZENECA AB 2017 - 2022
  • Private Grant  awarded by THERACOS SUB, LLC 2017 - 2022
  • Private Grant  awarded by GAN & LEE PHARMACEUTICAL 2018 - 2022
  • Private Grant  awarded by GAN & LEE PHARMACEUTICAL 2018 - 2022
  • Private Grant  awarded by ALLERGAN SALES, LLC 2019 - 2022
  • Private Grant  awarded by Sanofi US Services Inc 2018 - 2022
  • Private Grant  awarded by IRONWOOD PHARMACEUTICALS, INC. 2018 - 2022
  • Private Grant  awarded by Sanofi US Services Inc 2016 - 2021
  • Private Grant  awarded by Sanofi US Services Inc 2016 - 2020
  • Private Grant  awarded by XERIS PHARMACEUTICALS 2018 - 2020
  • Private Grant  awarded by Sanofi US Services Inc 2017 - 2020
  • Private Grant  awarded by ASTRAZENECA AB 2013 - 2019
  • Private Grant  awarded by XERIS PHARMACEUTICALS 2017 - 2019
  • Private Grant  awarded by Sanofi US Services Inc 2016 - 2018
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2014 - 2018
  • Cardiovascular Inflammation Reduction Trial (CIRT): A Randomized Double-Blind Placebo-Controlled, Event-Driven Trial of Weekly Low-Dose Methotrexate (LDM) in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients  awarded by Brigham and Women's Hospital 2013 - 2018
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014 - 2018
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014 - 2018
  • Private Grant  awarded by Janssen 2010 - 2017
  • Private Grant  awarded by Sanofi US Services Inc 2009 - 2016
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014 - 2016
  • Private Grant  awarded by MERCK & COMPANY, INC. 2013 - 2016
  • Private Grant  awarded by GI DYNAMICS, INC. 2013 - 2016
  • Diabetic Macular Edema Found by OCT Utilization at Non-Ophthalmic Diabetes Care Visits  awarded by Joslin Diabetes Center 2014 - 2016
  • Private Grant  awarded by BIODEL, INC. 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2015
  • Private Grant  awarded by MERCK & COMPANY, INC. 2013 - 2014
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2014
  • Private Grant  awarded by Janssen 2013 - 2014
  • A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2014
  • Private Grant  awarded by ELI LILLY AND COMPANY 2011 - 2014
  • Private Grant  awarded by Sanofi US Services Inc 2011 - 2014
  • Private Grant  awarded by MACROGENICS 2009 - 2013
  • Private Grant  awarded by PAMLAB LLC 2008 - 2013
  • Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus - SAVOR-TIMI53. A Multicentre, Randomised, Double-Blind, Placbeo-Controlled Phase IV Trial to Evaluate the Effects of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infraction or Ischaemic Stroke in Patients with Type 2 Diabetes  awarded by Brigham and Women's Hospital 2010 - 2013
  • Private Grant  awarded by GlaxoSmithKline 2008 - 2013
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2010 - 2013
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2013
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2013
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2009 - 2013
  • Private Grant  awarded by BAYHILL THERAPEUTICS 2008 - 2013
  • Private Grant  awarded by OSIRIS THERAPEUTICS, INC. 2008 - 2013
  • Private Grant  awarded by FIBROGEN, INC. 2008 - 2013
  • Private Grant  awarded by Pfizer Pharmaceuticals 2007 - 2013
  • Private Grant  awarded by TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. 2007 - 2012
  • Private Grant  awarded by GlaxoSmithKline 2006 - 2012
  • Private Grant  awarded by TOLERX, INC. 2007 - 2012
  • Private Grant  awarded by ANDROMEDA BIOTECH LTD. 2010 - 2012
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2008 - 2012
  • Private Grant  awarded by ELI LILLY AND COMPANY 2010 - 2012
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2012
  • Targeting Inflammation using SALsalate for Type 2 Diabetes. TINSAL-T2D  awarded by Joslin Diabetes Center 2007 - 2012
  • Private Grant  awarded by MACROGENICS 2007 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2007 - 2012
  • Private Grant  awarded by TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. 2007 - 2012
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2009 - 2012
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2010 - 2011
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2010 - 2011
  • Private Grant  awarded by TOLERX, INC. 2006 - 2011
  • Private Grant  awarded by TOLERX, INC. 2010 - 2011
  • Private Grant  awarded by TOLERX, INC. 2010 - 2011
  • Private Grant  awarded by Sanofi US Services Inc 2006 - 2010
  • Investigator On

  • Private Grant  awarded by SHIRE-NPS PHARMACEUTICALS, INC. 2014 - 2024
  • Private Grant  awarded by CHIASMA, INC. 2017 - 2022
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2018 - 2021
  • Private Grant  awarded by SHIRE HUMAN GENETIC THERAPIES 2018 - 2021
  • Skeletal Muscle in Rheumatoid Arthritis  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by SHIRE DEVELOPMENT LLC 2018 - 2020
  • Private Grant  awarded by MILLENDO THERAPEUTICS 2017 - 2020
  • Private Grant  awarded by Bayer HealthCare 2015 - 2019
  • Implementation of Direct-to-Patient Telemedicine Healthcare Initiatives  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2017 - 2019
  • Repurposing of Verapamil as a Beta Cell Survival Therapy in T1D  awarded by Juvenile Diabetes Research Foundation International 2014 - 2019
  • Private Grant  awarded by CHIASMA, INC. 2016 - 2019
  • Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults  awarded by UNIVERSITY OF KENTUCKY (RESEARCH FOUNDATION) 2014 - 2019
  • Targeting TXNIP to Enhance Beta Cell Mass in T1D  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2014 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2018
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2016
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2013 - 2016
  • Exercise Intensity, Metabolic Rate & Insulin Sensitivity  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2016
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2014 - 2015
  • Shared Medical Appointments for Diabetes Mellitus  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2013 - 2014
  • Private Grant  awarded by INGREDION INCORPORATED 2011 - 2014
  • Private Grant  awarded by PROLOR BIOTECH 2013 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2012 - 2013
  • Private Grant  awarded by CORCEPT THERAPEUTICS, INC. 2009 - 2013
  • Private Grant  awarded by CORCEPT THERAPEUTICS, INC. 2008 - 2013
  • Pretreatment Genotyping at APOA5 and GCKR Loci and Response to Fenofibrate Therapy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2012
  • Private Grant  awarded by VERSARTIS INC. 2011 - 2012
  • Education And Training

  • University of Alabama at Birmingham, Other 2013
  • Doctor of Medicine, Autonomous University of Nuevo Leon 1990
  • Henry Ford Hospital Internal Medicine, Residency 1995
  • Barnes-Jewish Hospital - Washington University in St. Louis Endocrinology, Diabetes & Metabolism, Postdoctoral Fellowship 1997
  • Full Name

  • Fernando Ovalle